KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to $131.1 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) rose 2.10% to $131.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.1 million, marking a year-over-year increase of 2.10%. This contributed to the annual value of $129.0 million for FY2024, which is 2.78% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) is $131.1 million, which was up 0.53% from $130.4 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $131.1 million during Q3 2025, and registered a low of $117.0 million during Q1 2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $126.5 million in 2024 and averaged $127.3 million.
  • Data for Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 4.14% (in 2023) over the last 5 years.
  • Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $119.6 million in 2021, then grew by 2.87% to $123.0 million in 2022, then grew by 2.00% to $125.5 million in 2023, then rose by 2.78% to $129.0 million in 2024, then climbed by 2.10% to $131.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $131.1 million for Q3 2025, versus $130.4 million for Q2 2025 and $129.5 million for Q1 2025.